Stocks
I
SLP I
Apr 4, 2024, 6:33:12 AM
Simulations Plus Reports Stellar Second Quarter Fiscal 2024 Results
Simulations Plus, Inc. (NASDAQ: SLP), a premier provider of simulation and modeling software for pharmaceutical research, has recently announced its financial outcomes for the second quarter of the fiscal year 2024, which concluded on February 29, 2024. The report underscores significant growth and continued leadership in the pharmaceutical software industry.
Key Financial Highlights
- Total Revenue: Grew by 16% to $18.3 million.
- Software Revenue: Increased 11% to $11.6 million, accounting for 63% of the total revenue.
- Services Revenue: Saw a notable 27% increase to $6.7 million, making up 37% of the total revenue.
- Gross Profit: Rose to $13.2 million with a gross margin of 72%.
- Adjusted EBITDA: Stood at $7.1 million, representing 39% of total revenue.
- Net Income and EPS: Reported at $4.0 million and $0.20 respectively, maintaining stable earnings per share year-over-year.
Performance Over Six Months
- Total Revenue: Achieved an 18% increase to $32.8 million.
- Software Revenue: Up 16% to $19.2 million.
- Services Revenue: Grew 22% to $13.6 million.
- Gross Profit: Increased 3% to $23.1 million, with a gross margin of 70%.
- Adjusted EBITDA: Reached $10.5 million, equating to 32% of total revenue.
- Net Income and EPS: Improved to $6.0 million and $0.29, from $5.4 million and $0.26, respectively.
Management's Insight
Shawn O’Connor, CEO of Simulations Plus, highlighted the robust performance in both software and services segments, driven by increased adoption in the Clinical Pharmacology & Pharmacometrics and Cheminformatics business units. The growth in service revenues was attributed to the Quantitative Systems Pharmacology and Physiologically Based Pharmacokinetics units.
O'Connor also noted the positive signs in biotech funding, especially from companies with clinical trial candidates, and the healthier market conditions compared to last year. He expressed cautious optimism for the demand in Simulations Plus' offerings as the funding environment improves.
Strategic Focus and Fiscal 2024 Guidance
Simulations Plus remains committed to strategic investments and partnerships, particularly with early-stage technology companies, to bolster its R&D efforts and maintain its innovative edge. For fiscal 2024, the company maintains its revenue guidance at $66 to $69 million (a 10-15% increase) and anticipates diluted earnings per share to be between $0.66 and $0.68, indicating a 35-39% increase.
Stock Market Reaction
In response to these impressive second-quarter financial results, Simulations Plus' stock price witnessed a notable rise of 8.5% in after-market trading. This uptick reflects investor confidence in the company’s growth trajectory and strategic initiatives.
Dividend Announcement
The Board of Directors declared a quarterly cash dividend of $0.06 per share, payable on May 6, 2024, to shareholders of record as of April 29, 2024. Future dividends will be determined quarterly based on various financial and operational factors.